Neuroscience

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 years ago

Neuronetics Wins 2023 Bell Seal for Workplace Mental Health

The Company is recognized for its commitment to employees’ well-beingMALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…

2 years ago

Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system

Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab EmiratesBoston, MA, May 12, 2023 (GLOBE…

2 years ago

Psychedelic Science 2023 Announces Sessions and Select Featured Speakers for the Therapy and Practitioners Tracks for June Conference

Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl…

2 years ago

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology…

2 years ago

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In preclinical studies, PMN310 demonstrated the ability to selectively…

2 years ago

Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR

Achievement demonstrates Company’s commitment to rigorous standards for safe and effective productsMALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics,…

2 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Management to Host Conference CallBURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company…

2 years ago

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Recursion's Pipeline Recursion's internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry…

2 years ago

Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting

Data highlights the Company’s commitment to advancing TMS and improving patient outcomesMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics,…

2 years ago